Description
Geldanamycin derivative 17-AAG is an inhibitor of heat shock protein 90 (HSP90) that exhibits anti-inflammatory, anticancer chemotherapeutic, and antiviral activities. In endothelial cells, 17-AAG induces degradation of IκBα, attenuating NF-κB activation. 17-AAG induces Bax-dependent apoptosis in a variety of cancer models, both in vitro as well as in vivo. Additionally, 17-AAG inhibits replication of human cytomegalovirus.